Impact of the human papilloma virus (HPV) quadrivalent (types 6/11/16/18) vaccine in HPV-associated diseases in Spain;Impacto de la vacuna tetravalente frente al virus del papiloma humano (VPH) tipos 6, 11, 16 y 18 en las enfermedades asociadas al VPH en España

Progresos en Obstetricia y Ginecologia

Volumn 51, Issue 9, 2008, Pages 520-530

  Castellsagué, Xavier ^a   San Martín, María ^b   Cortés, Javier ^c   González, Antonio ^b   Remy, Vanessa ^d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Sanofi Pasteur MSD Departamento Médico Madrid España   (Spain)

^c Ginecología Oncológica Policlínica Miramar ^*  (Spain)

^d Sanofi Pasteur MSD Health Economic Unit Lyon   (Venezuela)

Author keywords

Cervical cancer screening; Cost effectiveness; Human papillomavirus; Vaccine

Indexed keywords

VIRUS VACCINE;

ARTICLE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INCIDENCE; PRECANCER; SPAIN; UTERINE CERVIX CANCER;

EID: 59749085257     PISSN: 03045013     EISSN: 15781453     Source Type: Journal    
DOI: 10.1016/S0304-5013(08)72326-4     Document Type: Article

References (34)

1. Baseman J.G., and Koutsky L.A. The epidemiology of human papillomavirus infections. J Clin Virol 32 (2005) S16-S24
2. Gustafsson L., Ponten J., Zack M., and Adami H.O. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 8 (1997) 755-763
3. Parkin D.M., Bray F., Ferlay J., and Pisani P. 2005 global cancer statistics. CA Cancer J Clin 55 (2005) 74-108
4. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2002: Cancer incidence, mortality and prevalence world wide. 2004. IARC CancerBase No. 5. version 2.0, IARCPress, Lyon.
5. Cerdá Mota T, Salas Trejo D. Programas de detección precoz del cáncer. Situación del cáncer en España. [Accedido Oct 2007.] Ministerio de Sanidad y Consumo. Disponible en: http://www.webpacientes.org/docs/cancer-msc.pdf
6. Bray F., Loos A.H., McCarron P., Weiderpass E., Arbyn M., Møller H., et al. Trends in Cervical Squamous Cell Carcinoma Incidence in 13 European Countries: Changing Risk and the Effects of Screening. Cancer Epidemiol Biomarkers Prev 14 (2005) 677-686
7. European Agency for the Evaluation of Medicinal Products (EMEA). European Public Assessment Report (EPAR). Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/gardasil/ H-703-PI-en.pdf
8. Markowitz L, Dunne E, Gilsdorf J. Development of recommendations for HPV vaccine use in the United States. Papillomavirus 22nd International Conference and Clinical Workshop 2005, Vancouver, British Columbia, Canada, 30 de abril-6 de mayo, 2005.
9. Weinstein M.C., Toy E.L., Sandberg E.A., Neuman P.J., Evans J.S., Kuntz K.M., et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 4 (2001) 348-361
10. Dasbach E.J., Elbasha E.H., and Insinga R.P. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 28 (2006) 88-100
11. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 (2003) 781-789
12. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9 (2003) 37-48
13. Bergeron C., Largeron N., McAllister R., Mathevet P., and Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 24 (2008) 10-19
14. López Alemany J.M., Cortés Bordoy J., and Gil de Miguel A. Estudio de coste-efectividad de la vacuna tetravalente del papilomavirus humano. Rev Esp Econ Salud 6 (2007) 400-408
15. Largeron N., Remy V., Oyee J., San-Martín M., Cortés, and Olmos L. Análisis de coste-efectividad de la vacunación frente al virus de papiloma humano (VPH) tipos 6, 11, 16 y 18 en España. Vacunas 9 (2008) 3-11
16. Vicente Ortún. 30.000 euros por AVAC. Economía y Salud. 2004; 17:49. Disponible en: www.econ.upf.es/∼ortun/publications/ 30000.pdf
17. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human paillomavirus vaccination strategies. Emerg Infect Dis 13 (2007) 28-41
18. Dasbach E.J., Insinga R.P., and Elbasha E.H. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 115 (2008) 947-956
19. Ministerio de Sanidad y consumo. Virus del papiloma humano. Situación actual, vacunas y perspectivas de su utilización. Febrero 2007. Disponible en: http://www.msc.es/profesionales/saludPublica/ prevPromocion/vacunaciones/docs/VPH_2007.pdf
20. Ministerio de Sanidad y Consumo. Coberturas de vacunación. [Accedido Marzo 2007.] Disponible en: http://www.msc.es/profesionales/saludPublica/prevPromocion/vacunaciones/ coberturas.htm
21. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
22. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007) 4931-4939
23. Castellsagué X, Rémy V, Puig-Tintoré LM, Sainz de la Cuesta R, San-Martín M, Cohet C. Cervical Cancer screening and management costs in Spain. XXXIII European Congress of Cytology. Madrid, España. 14-17 de octubre de 2007.
24. Castellsague X, Cohet C, Puig-Tintore LM, Olmos Acebes L, Salinas J, San Martin M. et al. Burden of genital warts in Spain. 7th International Multidisciplinary Congress - European Research Organization on Genital Infection and Neoplasia (EUROGIN). Monaco, Montecarlo. 4-6 de octubre de 2007.
25. Gil A., San-Martín M., Gil R., Hernández V., Ribes J., and González A. Burden of hospital admissions for cervical cancer in Spain during 1999-2002. Human Vaccines 3 (2007) 276-280
26. Institut National du Cancer. Etudes et Expertises. Analyse économique des couts du cancer en France. Mars 2007. Disponible en : http://www.e-cancer.fr/v1/fichiers/public/etude_economieducancer. pdf
27. Dedes K.J., Szucs T.D., Bodis S., Joerger M., Lowy A., Russi E.W., et al. Management and costs of treating lung cancer patients in a university hospital. Pharmacoeconomics 22 (2004) 435-444
28. Brisson M., and Edmunds W.J. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 23 (2003) 76-82
29. Scherer A., and McLean A. Mathematical model of vaccination. Br Med Bull 62 (2002) 187-199
30. Winer R.L., Kiviat N.B., Hughes J.P., Adam D.E., Lee S.K., Kuypers J.M., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 191 (2005) 731-738
31. Edmunds W.J., Medley G.F., and Nokes D.J. Evaluating the cost-effectiveness of vaccination programmes: a dynamic approach. Stat Med 18 (1999) 3263-3282
32. Kohli M., Ferko N., Martin A., Franco E.L., Jenkins D., Gallivan S., et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 96 (2007) 143-150
33. Joura E.A., Leodolter S., Hernández-Ávila M., Wheeler C.M., Perez G., Koutsky L.A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 y 18) L1 virus-like-particles vaccine against high-grade vulval and vaginal lesion: a combined analysis of three randomized clinical trials. Lancet 369 (2007) 1693-1702
34. Merck & Co. Merck submits new cross-protection data for Gardasil ® to the FDA and seeks new indications for vaginal and vulvar cancers. Disponible en: http://www.merck.com/newsroom/press_releases/product/2007_0417.html